Johnson Matthey acquires pharmaceutical manufacturing capacity in Scotland
Former Glaxo site to be refurbished starting in early 2015
Johnson Matthey has acquired 109,000m2 of pharmaceutical manufacturing capacity in Scotland to meet increasing demand for customised pharmaceutical services and active ingredients using enhanced manufacturing capabilities.
Located in Annan, Dumfries and Galloway, the site was originally commissioned and constructed by Glaxo in 1980 and was most recently owned by Bakhu Pharma.
A ‘multimillion pound refurbishment’ will start next year to update and enhance the operational and quality standards of the facility, the company said. It is expected to be fully operational by early 2016.
The manufacturing capacity offers further opportunities to optimise efficiencies across Johnson Matthey’s global manufacturing assets, and the multipurpose capabilities at the plant complement the company’s portfolio of complex chemistry, catalysis and process technologies.
‘This strategic site addition significantly increases our global manufacturing capabilities and capacity,’ said John Fowler, Division Director at Johnson Matthey Fine Chemicals.
‘Combining the Annan site with our leading technologies will answer our customers’ needs for efficient production of pharmaceutical intermediates and APIs at the highest quality and compliance standards in the market.’
